Neuronal nicotinic receptors as new targets foramphetamine-induced oxidative damage and neurotoxicity

dc.contributor.authorPubill Sánchez, David
dc.contributor.authorGarcia Ratés, Sara
dc.contributor.authorCamarasa García, Jordi
dc.contributor.authorEscubedo Rafa, Elena
dc.date.accessioned2013-05-10T09:56:57Z
dc.date.available2013-05-10T09:56:57Z
dc.date.issued2011-06-15
dc.date.updated2013-05-10T09:56:57Z
dc.description.abstractAmphetamine derivatives such as methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) are drugs widely abused in a recreational context. This has led to concern because of the evidence that they are neurotoxic in animal models and cognitive impairments have been described in heavy abusers. The main targets of these drugs are plasmalemmal and vesicular monoamine transporters, leading to reverse transport and increased monoamine efflux to the synapse. As far as neurotoxicity is concerned, increased reactive oxygen species (ROS) production seems to be one of the main causes. Recent research has demonstrated that blockade of 7 nicotinic acetylcholine receptors (nAChR) inhibits METH- and MDMA-induced ROS production in striatal synaptosomes which is dependent on calcium and on NO-synthase activation. Moreover, 7 nAChR antagonists (methyllycaconitine and memantine) attenuated in vivo the neurotoxicity induced by METH and MDMA, and memantine prevented the cognitive impairment induced by these drugs. Radioligand binding experiments demonstrated that both drugs have affinity to 7 and heteromeric nAChR, with MDMA showing lower Ki values, while fluorescence calcium experiments indicated that MDMA behaves as a partial agonist on 7 and as an antagonist on heteromeric nAChR. Sustained Ca increase led to calpain and caspase-3 activation. In addition, modulatory effects of MDMA on 7 and heteromeric nAChR populations have been found.
dc.format.extent26 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec597321
dc.identifier.issn1424-8247
dc.identifier.urihttps://hdl.handle.net/2445/43290
dc.language.isoeng
dc.publisherMDPI Publishing
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.3390/ph4060822
dc.relation.ispartofPharmaceuticals, 2011, vol. 4, num. 6, p. 822-847
dc.relation.urihttp://dx.doi.org/10.3390/ph4060822
dc.rightscc-by (c) Pubill Sánchez, David et al., 2011
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationÈxtasi (Droga)
dc.subject.classificationReceptors nicotínics
dc.subject.classificationAmfetamines
dc.subject.classificationNeurotoxicologia
dc.subject.otherEcstasy (Drug)
dc.subject.otherNicotinic receptors
dc.subject.otherAmphetamines
dc.subject.otherNeurotoxicology
dc.titleNeuronal nicotinic receptors as new targets foramphetamine-induced oxidative damage and neurotoxicity
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
597321.pdf
Mida:
657.68 KB
Format:
Adobe Portable Document Format